PT2440230T - Regimes de tratamento para tratamento de doenças neurológicas - Google Patents

Regimes de tratamento para tratamento de doenças neurológicas

Info

Publication number
PT2440230T
PT2440230T PT107868598T PT10786859T PT2440230T PT 2440230 T PT2440230 T PT 2440230T PT 107868598 T PT107868598 T PT 107868598T PT 10786859 T PT10786859 T PT 10786859T PT 2440230 T PT2440230 T PT 2440230T
Authority
PT
Portugal
Prior art keywords
treatment
neurological disease
model systems
regimes
treatment regimes
Prior art date
Application number
PT107868598T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Nono Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono Inc filed Critical Nono Inc
Publication of PT2440230T publication Critical patent/PT2440230T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT107868598T 2009-06-10 2010-06-10 Regimes de tratamento para tratamento de doenças neurológicas PT2440230T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18598909P 2009-06-10 2009-06-10

Publications (1)

Publication Number Publication Date
PT2440230T true PT2440230T (pt) 2021-02-03

Family

ID=43309469

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107868598T PT2440230T (pt) 2009-06-10 2010-06-10 Regimes de tratamento para tratamento de doenças neurológicas

Country Status (14)

Country Link
US (2) US8940699B2 (cg-RX-API-DMAC7.html)
EP (2) EP3808366A1 (cg-RX-API-DMAC7.html)
JP (2) JP6005514B2 (cg-RX-API-DMAC7.html)
CN (1) CN102458441A (cg-RX-API-DMAC7.html)
AU (1) AU2010258664B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1010718A2 (cg-RX-API-DMAC7.html)
CA (1) CA2765169C (cg-RX-API-DMAC7.html)
DK (1) DK2440230T3 (cg-RX-API-DMAC7.html)
ES (1) ES2847293T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210112T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053131T2 (cg-RX-API-DMAC7.html)
PL (1) PL2440230T3 (cg-RX-API-DMAC7.html)
PT (1) PT2440230T (cg-RX-API-DMAC7.html)
WO (1) WO2010144721A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
CA2765169C (en) 2009-06-10 2019-06-18 Nono Inc. Model systems and treatment regimes for treatment of neurological disease
US9629892B2 (en) 2010-08-12 2017-04-25 Nono Inc. Treatment of penetrative injury to the brain
HRP20220519T1 (hr) 2011-06-24 2022-05-27 Nono Inc. Kombinacijska terapija ishemije
AU2012354072B2 (en) * 2011-12-13 2017-04-27 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
AU2013204309A1 (en) * 2012-11-13 2014-05-29 Biodiem Limited Therapeutic Compounds and Uses Thereof
TR201905787T4 (tr) * 2012-11-28 2019-05-21 Nono Inc Liyofilize TAT-NR2B9C formülasyonu.
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
UA123820C2 (uk) * 2014-05-28 2021-06-09 Ноно Інк. Хлоридна сіль пептиду tat-nr2b9c
US20190134150A1 (en) * 2016-04-27 2019-05-09 Biocells (Beijing) Biotech Co., Ltd. Therapeutic methods for excitatory neurotoxicity-related injuries
US11229675B2 (en) 2016-04-27 2022-01-25 Biocells (Beijing) Biotech Co., Ltd. Therapeutic peptides for excitatory neurotoxicity-related injuries
CN110049994B (zh) * 2016-12-08 2023-05-02 拜西欧斯(北京)生物技术有限公司 一种缀合物及其应用
KR102403089B1 (ko) * 2017-07-05 2022-06-02 바이오셀즈(베이징) 바이오테크 코., 엘티디. 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도
CN110799547B (zh) * 2017-07-05 2023-02-28 拜西欧斯(北京)生物技术有限公司 用于治疗、改善或预防神经系统相关病症的化合物及其用途
EP3693001A4 (en) 2017-09-30 2021-07-07 Biocells (Beijing) Biotech Co., Ltd. PEPTIDIC COMPOSITION ALLOWING THE TREATMENT OF INJURIES RELATED TO EXCITING NEUROTOXICITY
CN113121641B (zh) 2021-03-11 2022-11-01 武汉英纳氏药业有限公司 一类多功能多肽及其在医药领域的应用
CN113150065B (zh) 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
CN113735938B (zh) * 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
CN114642402A (zh) * 2022-03-07 2022-06-21 翰博瑞强(上海)医药科技有限公司 一种用于预测药物对心脏毒性影响的方法及心电图设备
CN114469084B (zh) * 2022-04-02 2022-06-24 剑博微电子(深圳)有限公司 一种基于高精度adc的血氧监测系统

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148711A1 (en) 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
GB0025473D0 (en) 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
CA2505479A1 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
WO2004071531A1 (en) 2003-02-13 2004-08-26 Licentia Oy Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
BRPI0409865A (pt) 2003-05-02 2006-05-16 Paion Deutschland Gmbh injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia
CA2657665C (en) * 2006-07-11 2015-06-02 Arbor Vita Corporation Method and compositions for treating stroke with fever
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
ES2446292T3 (es) * 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
WO2009006611A1 (en) 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
PL2320927T3 (pl) 2008-07-09 2016-02-29 Univ Copenhagen Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD
CA2765169C (en) 2009-06-10 2019-06-18 Nono Inc. Model systems and treatment regimes for treatment of neurological disease
HRP20220519T1 (hr) 2011-06-24 2022-05-27 Nono Inc. Kombinacijska terapija ishemije
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
AU2012354072B2 (en) 2011-12-13 2017-04-27 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia

Also Published As

Publication number Publication date
US8940699B2 (en) 2015-01-27
US20120269733A1 (en) 2012-10-25
WO2010144721A3 (en) 2011-04-21
AU2010258664B2 (en) 2015-05-28
HUE053131T2 (hu) 2021-06-28
CA2765169C (en) 2019-06-18
BRPI1010718A2 (pt) 2016-03-15
EP2440230A4 (en) 2014-05-28
EP2440230A2 (en) 2012-04-18
AU2010258664A1 (en) 2012-01-12
CA2765169A1 (en) 2010-12-16
DK2440230T3 (da) 2021-01-18
ES2847293T3 (es) 2021-08-02
JP2012530057A (ja) 2012-11-29
JP6220371B2 (ja) 2017-10-25
US20150202253A1 (en) 2015-07-23
US9610323B2 (en) 2017-04-04
JP2016041731A (ja) 2016-03-31
CN102458441A (zh) 2012-05-16
EP2440230B1 (en) 2020-11-11
WO2010144721A2 (en) 2010-12-16
PL2440230T3 (pl) 2021-06-14
EP3808366A1 (en) 2021-04-21
JP6005514B2 (ja) 2016-10-12
HRP20210112T1 (hr) 2021-04-16

Similar Documents

Publication Publication Date Title
HUE053131T2 (hu) Kezelési rendszer neurológiai betegség kezelésére
IL217777A0 (en) Methods for treatment of pain
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
IL218309A0 (en) Systems and methods for stimulation of neuronal activity
IL211857A0 (en) Method and system for neurological treatment
EP2432394A4 (en) SYSTEMS AND METHOD FOR THE ANALYSIS AND TREATMENT OF A BODY LUMEN
GB0908193D0 (en) Treatment of disease state
AU339607S (en) Medical device for treatment of sleep disorders
PT2435825E (pt) Métodos para o tratamento de doenças
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
ZA201109449B (en) Methods and products for treatment of diseases
IL216951A0 (en) Method for treatment of diseases
GB0918392D0 (en) Diagnostic and therapeutic methods
PL2477656T3 (pl) Leczenie stanów neurologicznych
HU0900195D0 (en) Diagnosis and treatment of gluten-induced autoimmune diseases
GB201017857D0 (en) Methods for diagnosis and methods of treatment
GB0908666D0 (en) Treatment of proteostatic disease
GB0911931D0 (en) Treatment of learning disabilities and behavioural disorders
GB0817859D0 (en) Treatment of proteostatic disease
GB0819543D0 (en) Treatment of proteostatic disease
GB201010685D0 (en) Treatment of learning disabilities and behavioural disorders
GB201014519D0 (en) In vivo screened models for treatment of isoQC-related disorders
GB0901832D0 (en) Respiratory disease treatment